Small Interfering Rna Delivery
Small Interfering Rna Delivery - Related Videos
08:36
Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae
0 Views •
Cited by 94 •
2015
Here we describe a procedure for inhibiting gene function in disease vector mosquitoes through the use of chitosan/interfering RNA nanoparticles that are ingested by larvae.
02:30
siRNA - Small Interfering RNAs
0 Views •
2020
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements. In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
09:36
Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo
0 Views •
Cited by 21 •
2019
We describe a method of using polyethyleneimine (PEI)-coated superparamagnetic iron oxide nanoparticles for transfecting macrophages with siRNA. These nanoparticles can efficiently deliver siRNA to macrophages in vitro and in vivo and silence target gene expression.
04:34
siRNA Reverse Transfection-Based Gene Silencing In Vitro: A Procedure to Deliver Small Interfering RNA in Cultured Cells to Inactivate Target Gene Expression
0 Views •
2025
In this video, we describe a procedure to perform reverse transfection of siRNA into adipocytes to modulate the expression of a target protein.
02:30
Small interfering RNAs (siRNA)
0 Views •
2023
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements. In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
FAQs
After delivery into the cell, siRNA is incorporated into the RNA-induced silencing complex, or RISC. One siRNA strand remains associated with the complex and provides the sequence needed to recognize a complementary messenger RNA. RISC then promotes degradation of that messenger RNA, reducing production of the corresponding protein and enabling selective investigation of harmful gene activity.
Cellular uptake alone does not ensure effective gene silencing. Once a carrier enters the cell, the siRNA must be released from the carrier and escape the endosomal compartment so it can reach the intracellular machinery that performs silencing. Delivery systems are therefore evaluated not only for uptake, but also for release and endosomal escape.
These delivery strategies address several barriers that limit siRNA function. Lipid nanoparticles and polymeric carriers can protect the RNA from degradation, while carriers or conjugated molecules can help direct it toward target tissues. The overall design must also support intracellular release and endosomal escape, linking protection and targeting with downstream gene-silencing activity.
Effective silencing depends on a sequence of connected events: the siRNA must remain protected, reach the intended tissue, enter target cells, separate from its carrier, and escape the endosome. Failure at any stage can reduce the amount available to RISC. Consequently, delivery performance reflects the combined effects of stability, targeting, uptake, release, and intracellular access.
A typical evaluation follows the delivery pathway: select an siRNA directed against the gene of interest, package or conjugate it with a delivery system, assess protection and tissue targeting, examine cellular uptake and release, and determine whether the intended messenger RNA is degraded. The final outcome is reduced expression of the selected gene in the relevant experimental or medical context.
The approach is relevant when disease is driven by a harmful gene whose expression can be selectively reduced. Its medical applications include investigating and developing treatments for cancer, infection, and genetic disorders. By connecting sequence-specific messenger RNA degradation with tissue-directed delivery, these systems support the broader goal of developing more precise therapies for disease-related gene activity.